1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : SPECIALTY PHARMACEUTICALS
  4. ENVERIC BIOSCIENCES INC
Enveric Biosciences Inc
XNAS: ENVB
Download real time
1.45-0.07(-4.61%)
89.06% Fall from 52W High
50,177
XNAS Volume

XNAS 09 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Enveric Biosciences Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Enveric Biosciences Inc quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
  • NEUTRAL

    Quarterly Revenue Enveric Biosciences Inc Jun-2026 Quarterly Revenue is $0 Million which is growth of 0% YoY.

  • NEGATIVE

    Quarterly Net Profit Enveric Biosciences Inc Jun-2026 Quarterly Net Profit is $-3 Million which is growth of -20.2% YoY.

Enveric Biosciences Inc, Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphJun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Sep '23Jun '23
Operating Rev.
Cost Of Rev.
-------------
Gross Profit
-------------
⌄
31.62.21.92.52.23.22.11.92.54.23.55.8
Operating Profit
-3-1.6-2.2-1.9-2.5-2.2-3.2-2.1-1.9-2.5-4.2-3.5-5.8
⌄
Profit Before Tax
-3-1.6-2.2-1.9-2.5-2.2-3.2-2.1-1.9-2.5-3.4-2.8-6.4
Tax
000-
⌄
-3-1.6-4-3.4-2.5-2.2-3.2-2.1-1.9-2.5-3.4-2.8-6.4
Diluted NI Avail to Com Stockholders Ann.
-3-1.6-4-3.4-2.5-2.2-3.2-2.1-1.9-2.5-3.4-2.8-6.4
Basic EPS
-0.8-1.1-0.5-10.8-11.6-14.6-57.5-43.2-45-109.8-264.6-234-547.2
Diluted EPS After ExtraOrdinary
-0.8-1.1-3.8-10.8-11.6-14.6-57.6-43.2-45.4-110.6-315.5-275.4-495.8
Number Of Shares End
41.51.10.30.20.20.10.100000
Net Income Continuing Discontinued Operations
-3-1.6-2.2-1.9-2.5-2.2-3.2-2.1-1.9-2.5-3.4-2.8-6.4
Normalized Income
-2.9-1.5-2-1.7-2.3-2-2.8-1.7-1.5-2.2-3.8-3-4.9
Interest Income
------------
Interest
-------------
Net Interest Income
EBIT
-3-1.6-2.2-1.9-2.5-2.2-3.2-2.1-1.9-2.5-3.4-2.8-6.4
EBITDA
-3-1.6-2.2-1.8-2.5-2.1-3.1-2-1.8-2.4-3.3-2.7-6.2
Reconciled Cost Of Rev.
-------------
Reconciled Depr.
000000.10.10.10.10.10.10.10.1
Profit From Continuing Operations
-3-1.6-2.2-1.9-2.5-2.2-3.2-2.1-1.9-2.5-3.4-2.8-6.4
Normalized EBITDA
-3-1.6-2.2-1.8-2.5-2.1-3.1-2-1.8-2.4-5-4-5
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Enveric Biosciences Inc competitor comparison and performance snapshot within industry

Enveric Biosciences Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEUTRAL

    Annual Revenue Enveric Biosciences Inc Annual Revenue is $0 Million which is growth of 0% YoY.

  • POSITIVE

    Annual Net Profit Enveric Biosciences Inc Annual Net Profit is $-9 Million which is growth of 8.4% YoY.

Enveric Biosciences Inc, Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsTTMDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
⌄
-
-
 39.94348.636.216
Cost Of Rev. Ann.
-
-
 ------31.83438.429.610.2
Gross Profit Ann.
-
-
 -----8.2910.26.55.8
Operating Exp. Ann.
-23.9%
6.6%
8.78.89.618.32027.16.414.513.721.710.36
Operating Profit Ann.
-
-
-8.7-8.8-9.6-18.3-20-27.1-6.4-6.3-4.7-11.5-3.8-0.2
⌄
-
-
-0-0-0-0.5-0.7-0.7-0.6-0.8-0.2
Other Exp. Ann.
-
-43.9%
 0.110-29.4-0.81.8-5.10.6-2-1.7
PBT Ann.
-
-
-8.7-8.8-9.6-17.3-20-56.4-6.9-5.2-10.6-11.5-6.5-2
Tax Ann.
-
-
 00-1.5-7.5-0.46.4-2.4-3.8-0.1
⌄
-
-
-12.1-12.1-9.6-17.5-18.8-49-6.9-6-19.5-11.2-2.8-1.9
Diluted NI Avail to Com Stockholders Ann.
-
-
-12.1-12.1-9.6-17.5-18.8-49-6.9-6-19.5-11.2-2.8-1.9
EPS Ann.
-
-
 -36.2-228.5-1,456.2-2,340-18,630-10,710-101,880-738,000.1-675,000.1-189,000-153,000
Diluted EPS Ann.
-
-
 -36.2-228.5-1,456.2-2,340-18,630-10,710-101,880-738,000.1-675,000.1-189,000-153,000
Number Of Shares End
-
-
 1.10.100-
Total Exp. Ann.
-23.9%
6.6%
 8.89.618.32027.16.446.247.760.139.916.2
Net Income Continuing Discontinued Operations Ann.
-
-
-8.7-8.8-9.6-17.3-18.5-49-6.9-5.6-16.9-9.1-2.8-1.9
Normalized Income Ann.
-
-
-8.1-8-8.4-16.4-8.626.1-4.9-6.5-3.2-3.1-1-0.3
Interest Income Ann.
-
-
 -------0.1
Interest Ann.
-
-
 ---000.50.70.70.60.80.2
EBITDA Ann.
-
-
-8.6-8.6-9.2-16.9-19.5-55.7-6.3-2.3-6.9-7.7-4.4-1.7
Reconciled Cost Of Rev. Ann.
-
-
 ------31.83438.429.610.2
Reconciled Depr. Ann.
-20.6%
14.9%
0.20.20.30.40.40.70.12.32.93.21.40.2
Profit From Continuing Operations Ann.
-
-
-8.7-8.8-9.6-17.3-18.5-49-6.9-6-16.9-11.2-2.8-1.9
Normalized EBITDA Ann.
-
-
-8.6-8.6-9.3-18.9-19.5-26.4-6.3-4.1-1.7-7.2-2.80
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Operating Exp. Ann.
1Y CHG
-8.3%
2Y CAGR
-30.7%
3Y CAGR
-23.9%
5Y CAGR
6.6%
7Y CAGR
-6.1%
10Y CAGR
3.9%
Operating Expenses Annual Cr is falling faster than historical averages.

Enveric Biosciences Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Total Shareholders Fund Enveric Biosciences Inc Dec-2025 Total Shareholders Fund is $4 Million which is growth of 162.3% YoY.

  • POSITIVE

    Total Assets Enveric Biosciences Inc Dec-2025 Total Assets is $5 Million which is growth of 65.3% YoY.

Enveric Biosciences Inc, Balance Sheet, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
⌄
-36.2%
4.5%
5.13.14.319.626.74.12529.652.239.513.8
⌄
-39.2%
5.2%
0.91.52.344.40.714.418.932.827.813.6
⌄
-34.1%
4.3%
4.21.6214.722.33.410.610.819.411.70.3
Total Capitalization Ann.
-34.1%
4.3%
4.21.6214.722.33.410.610.821.813.25.3
Tangible Assets Ann.
-33.5%
21.3%
4.21.61.814.313.81.6-6.7-8.8-11.9-14.2-6.3
Working Capital Ann.
-34.8%
20.1%
41.21.214.415.71.6-6.8-4.6-15.7-2.6-1.4
Invested Capital Ann.
-34.1%
4.3%
4.21.6214.722.33.415.51626.616.76.5
Tangible Book Value Ann.
-33.5%
21.3%
4.21.61.814.313.81.6-6.7-8.8-11.9-14.2-6.3
Borrowings Ann.
-
-
--0.10.2-4.95.27.256.2
Net Debt Ann.
-
-
------4.53.82.33.74.4
Share Issued Ann.
-
-
1.10.100
Number Of Shares End
-
-
1.10.100-
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Assets Ann.
1Y CHG
64.5%
2Y CAGR
8.9%
3Y CAGR
-36.2%
5Y CAGR
4.5%
7Y CAGR
-22.2%
10Y CAGR
-9.5%
Total Assets Annual growth is higher than historical averages.
Total Current Liabilities Ann.
1Y CHG
-40%
2Y CAGR
-37.4%
3Y CAGR
-39.2%
5Y CAGR
5.2%
7Y CAGR
-32.9%
10Y CAGR
-20.2%
Total Current Liabilities Annual Cr is falling faster than historical averages.
Total ShareHolders Funds Ann.
1Y CHG
162.5%
2Y CAGR
44.9%
3Y CAGR
-34.1%
5Y CAGR
4.3%
7Y CAGR
-12.6%
10Y CAGR
30.2%
Total ShareHolders Funds Annual growth is higher than historical averages.

Enveric Biosciences Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Book Value Per Share Enveric Biosciences Inc Book Value Per Share is $2 which is growth of -89.9% YoY.

  • NEUTRAL

    ROE Enveric Biosciences Inc ROE is 0% which is growth of 0% YoY.

Enveric Biosciences Inc, Ratios, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
RoA Ann. %
-
-
--259.40%-146.39%-81.26%-317.87%-47.18%-22.07%-47.61%-24.35%-10.43%-27.32%
ROE Ann. %
-
-
--539.57%-209.99%-101.68%-381.31%-98.07%-56.43%-129.02%-71.79%-46.67%-1,484.92%
ROIC %
-
-
--113.8-156.5-46.7-107.9-26.8-15.3-79.6-6.38.6-
OPM Ann. %
-
-
-------15.85%-10.97%-23.64%-10.50%-1.34%
Inventory Turnover Ratio Ann.
-
-
-----------
Asset Turnover Ann. %
-
-
------1.51.11.11.42.3
Working Capital Turnover Ann.
-
-
-5.9-9.3-3.1-13.7-11.4
Quick Ratio Ann.
-
-
-1.51.14.48.32.30.50.60.50.80.8
Current Ratio Ann.
-
-
-1.81.54.68.53.40.50.70.50.80.8
Interest Coverage Ratio Ann.
-
-
----3,801.1-5,469.3-14.4-6.6-13.5-18.9-7.7-7.5
LT Debt To Equity Ann.
-
-
-------0.10.119.3
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Enveric Biosciences Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Cash From Operating Activity Enveric Biosciences Inc Cash From Operating Activity is $-8 Million which is growth of -5.4% YoY.

  • NEUTRAL

    Net Cash Flow Enveric Biosciences Inc Net Cash Flow is $0 Million which is growth of 0% YoY.

Enveric Biosciences Inc, Cash Flow, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
⌄
-
-
-8.1-7.7-14.1-17.2-11.5-3.9-2.5-2.6-2.7-2.7-3.7
⌄
-
-
-0-0.62.2-0-0.3-3.6-0.8-6.6-1.5
⌄
-16.5%
14%
10.67.7-1.318.224.95.51.82.77.18.86.2
Cash Plus Cash Eqv. End Of Year Ann.
-35.7%
24%
4.72.22.317.717.41.60.41.44.91.41.9
Net Increase In Cash Plus Cash Eqv.s Ann.
68.7%
8.4%
2.4-0.1-15.40.515.61.6-0.9-3.53.5-0.51.1
Cash Plus Cash Eqv. Begin Of Year Ann.
-49.8%
-
2.22.317.717.41.601.44.91.41.90.8
Income Tax Paid Supplemental Data Ann.
-
-
00---
Interest Paid Supplemental Data Ann.
-
-
00-0.50.60.50.4-
Capex Ann.
-
-
---0-0.6-0.9-0-0.1--3.7-1.7
Issuance Of Capital Stock Ann.
-30%
63.8%
5.93.417.221.60.52.16.34.95
Issuance Of Debt Ann.
-
-
----1.91-2.23.86.2
Repayment Of Debt Ann.
-
-
-----0.2-1.3-2---
Repurchase Of Capital Stock Ann.
-
-
--1.1--------
Free Cash Flow Ann.
-
-
-8.1-7.7-14.1-17.7-12.3-3.9-2.5-2.6-2.8-6.4-5.4
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Cash from Financing Act. Ann.
1Y CHG
37.7%
3Y CAGR
-16.5%
5Y CAGR
14%
7Y CAGR
21.6%
10Y CAGR
5.5%
Cash from Financing Annual Activity growth is higher than historical averages.
×